- Home
- TOUR vs MREO Comparison
TOUR vs MREO Comparison
Compare TOUR & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOUR | MREO |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | China | United Kingdom |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 53.4M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TOUR | MREO |
|---|---|---|
| Price | $5.10 | $0.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 9.4K | ★ 1.0M |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $17.30 | $5,184.20 |
| Revenue Next Year | $14.00 | $55.51 |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.20 |
| 52 Week High | $7.79 | $2.37 |
Technical Indicators
Market Signals| Indicator | TOUR | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 42.09 |
| Support Level | $0.66 | $0.28 |
| Resistance Level | $5.28 | $0.35 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 57.14 | 12.54 |
Price Performance
Historical ComparisonAbout TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).